Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt N/A
BAX's Cash to Debt is ranked lower than
55% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.63 vs. BAX: N/A )
Ranked among companies with meaningful Cash to Debt only.
BAX' s Cash to Debt Range Over the Past 10 Years
Min: 0.17  Med: 0.31 Max: 1.13
Current: N/A
0.17
1.13
Equity to Asset 0.42
BAX's Equity to Asset is ranked lower than
78% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. BAX: 0.42 )
Ranked among companies with meaningful Equity to Asset only.
BAX' s Equity to Asset Range Over the Past 10 Years
Min: 0.24  Med: 0.34 Max: 0.45
Current: 0.42
0.24
0.45
Interest Coverage 6.24
BAX's Interest Coverage is ranked lower than
63% of the 122 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.66 vs. BAX: 6.24 )
Ranked among companies with meaningful Interest Coverage only.
BAX' s Interest Coverage Range Over the Past 10 Years
Min: 3.08  Med: 17.86 Max: 32.02
Current: 6.24
3.08
32.02
F-Score: 5
Z-Score: 3.01
M-Score: -2.73
WACC vs ROIC
6.38%
5.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 7.86
BAX's Operating margin (%) is ranked higher than
62% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.20 vs. BAX: 7.86 )
Ranked among companies with meaningful Operating margin (%) only.
BAX' s Operating margin (%) Range Over the Past 10 Years
Min: 4.5  Med: 18.50 Max: 22.9
Current: 7.86
4.5
22.9
Net-margin (%) 34.50
BAX's Net-margin (%) is ranked higher than
66% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.71 vs. BAX: 34.50 )
Ranked among companies with meaningful Net-margin (%) only.
BAX' s Net-margin (%) Range Over the Past 10 Years
Min: 9.71  Med: 16.16 Max: 23.3
Current: 34.5
9.71
23.3
ROE (%) 48.93
BAX's ROE (%) is ranked higher than
74% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.01 vs. BAX: 48.93 )
Ranked among companies with meaningful ROE (%) only.
BAX' s ROE (%) Range Over the Past 10 Years
Min: 11.41  Med: 28.27 Max: 34.4
Current: 48.93
11.41
34.4
ROA (%) 16.04
BAX's ROA (%) is ranked higher than
61% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.86 vs. BAX: 16.04 )
Ranked among companies with meaningful ROA (%) only.
BAX' s ROA (%) Range Over the Past 10 Years
Min: 4.11  Med: 10.79 Max: 13.46
Current: 16.04
4.11
13.46
ROC (Joel Greenblatt) (%) 10.75
BAX's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.00 vs. BAX: 10.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
BAX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 5.65  Med: 37.11 Max: 43.28
Current: 10.75
5.65
43.28
Revenue Growth (3Y)(%) -10.20
BAX's Revenue Growth (3Y)(%) is ranked lower than
81% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. BAX: -10.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
BAX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -10.2  Med: 6.70 Max: 17.3
Current: -10.2
-10.2
17.3
EBITDA Growth (3Y)(%) -28.30
BAX's EBITDA Growth (3Y)(%) is ranked lower than
90% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.30 vs. BAX: -28.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
BAX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.3  Med: 6.60 Max: 33.1
Current: -28.3
-28.3
33.1
EPS Growth (3Y)(%) -44.00
BAX's EPS Growth (3Y)(%) is ranked lower than
92% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. BAX: -44.00 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
BAX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -44  Med: 7.10 Max: 61.5
Current: -44
-44
61.5
» BAX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-29)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

BAX Guru Trades in Q2 2015

Ken Fisher 3,652 sh (New)
Daniel Loeb 3,950,000 sh (New)
Vanguard Health Care Fund 1,945,220 sh (New)
Pioneer Investments 15,600 sh (New)
Steven Cohen 255,800 sh (New)
First Eagle Investment 842,686 sh (+76507.82%)
Paul Tudor Jones 105,328 sh (+98.70%)
Murray Stahl 13,022 sh (+25.55%)
David Dreman 9,319 sh (+18.32%)
John Keeley 61,580 sh (+15.19%)
Mario Gabelli 183,950 sh (+11.59%)
Charles Brandes 241,872 sh (+5.17%)
John Buckingham 104,306 sh (+1.27%)
Diamond Hill Capital 1,764,756 sh (+0.59%)
Jeff Auxier 24,731 sh (+0.41%)
Richard Pzena 5,030,632 sh (+0.04%)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Dodge & Cox 3,382 sh (unchged)
Scott Black Sold Out
Jim Simons Sold Out
Joel Greenblatt Sold Out
Mairs and Power 2,333,273 sh (-0.11%)
Tweedy Browne 2,543,966 sh (-0.81%)
John Rogers 61,951 sh (-1.59%)
Manning & Napier Advisors, Inc 177,990 sh (-5.72%)
John Hussman 2,700 sh (-27.52%)
Jeremy Grantham 185,204 sh (-56.24%)
» More
Q3 2015

BAX Guru Trades in Q3 2015

Tom Gayner 10,000 sh (New)
George Soros 509,700 sh (New)
Louis Moore Bacon 210,000 sh (New)
Jana Partners 12,580,576 sh (New)
Jim Simons 728,232 sh (New)
Daniel Loeb 53,850,000 sh (+1263.29%)
Vanguard Health Care Fund 7,195,480 sh (+269.91%)
John Keeley 82,100 sh (+33.32%)
Charles Brandes 311,631 sh (+28.84%)
First Eagle Investment 1,056,700 sh (+25.40%)
Manning & Napier Advisors, Inc 203,293 sh (+14.22%)
Murray Stahl 13,972 sh (+7.30%)
John Rogers 66,331 sh (+7.07%)
Tweedy Browne Global Value 1,094,821 sh (unchged)
John Hussman 2,700 sh (unchged)
Signature Select Canadian Fund Sold Out
Ken Fisher Sold Out
Steven Cohen Sold Out
David Dreman Sold Out
Dodge & Cox Sold Out
Pioneer Investments Sold Out
Diamond Hill Capital Sold Out
Jeff Auxier 24,631 sh (-0.40%)
Mairs and Power 2,298,348 sh (-1.50%)
Tweedy Browne 2,498,141 sh (-1.80%)
Richard Pzena 4,863,446 sh (-3.32%)
Mario Gabelli 157,850 sh (-14.19%)
John Buckingham 87,389 sh (-16.22%)
Paul Tudor Jones 79,931 sh (-24.11%)
Jeremy Grantham 55,046 sh (-70.28%)
» More
Q4 2015

BAX Guru Trades in Q4 2015

Steven Cohen 888,700 sh (New)
Lee Ainslie 30,140 sh (New)
David Einhorn 503,500 sh (New)
Louis Moore Bacon 620,000 sh (+195.24%)
Tom Gayner 22,000 sh (+120.00%)
Vanguard Health Care Fund 9,558,280 sh (+32.84%)
Charles Brandes 315,373 sh (+1.20%)
Murray Stahl 14,022 sh (+0.36%)
Daniel Loeb 53,850,000 sh (unchged)
Tweedy Browne Global Value 1,094,821 sh (unchged)
John Hussman Sold Out
Paul Tudor Jones 79,893 sh (-0.05%)
Tweedy Browne 2,495,682 sh (-0.10%)
Mario Gabelli 156,900 sh (-0.60%)
John Buckingham 85,849 sh (-1.76%)
Mairs and Power 2,252,752 sh (-1.98%)
Richard Pzena 4,736,982 sh (-2.60%)
George Soros 495,000 sh (-2.88%)
John Rogers 63,595 sh (-4.12%)
Jeremy Grantham 52,246 sh (-5.09%)
Jeff Auxier 20,831 sh (-15.43%)
Manning & Napier Advisors, Inc 160,214 sh (-21.19%)
First Eagle Investment 808,879 sh (-23.45%)
Jim Simons 492,132 sh (-32.42%)
John Keeley 50,550 sh (-38.43%)
Jana Partners 5,709,178 sh (-54.62%)
» More
Q1 2016

BAX Guru Trades in Q1 2016

Murray Stahl 14,122 sh (+0.71%)
Tweedy Browne Global Value 1,094,821 sh (unchged)
Manning & Napier Advisors, Inc 149,096 sh (-6.94%)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Baxter International Inc

Diamond Hill Capital Comments on Baxter International Inc - Jul 25, 2014

We sold our shares of medical supply manufacturer Baxter International, Inc. (BAX) after we marginally lowered our intrinsic value estimate to reflect an increased likelihood of more meaningful competition for its Hemophilia franchise. This resulted in an insufficient discount to our estimate of intrinsic value, and we exited the position.

From Diamond Hill Capital (Trades, Portfolio)'s Select Fund Second Quarter 2014 Commentary.

Check out Diamond Hill Capital latest stock trades

Top Ranked Articles about Baxter International Inc

Dan Loeb's Third Point Portfolio Highly Concentrated The top position is in the green and tries to offset the negative performances of the other 2
Daniel Loeb´s Third Point disclosed an equity portfolio valued at some $9.86 billion at the end of the fourth quarter of 2015. The equity portfolio is mainly invested in Health Care (53%), Materials (17%) and Consumer Discretionary (11%) stocks. Read more...
Jana Partners Beefs Up Stake in ConAgra Foods Guru also purchases nearly 7.7 million shares of Microsoft
Jana Partners (Trades, Portfolio) is a value-oriented, event-driven manager that prefers to invest in companies that are experiencing or expected to experience significant change. At its website, Jana Partners (Trades, Portfolio) proclaims that it is “investing in change.” Read more...
Why Daniel Loeb Is Putting 15% of His Portfolio Into Baxter Loeb has taken a large stake in Baxter but remains rather quiet. What is the game plan?
Guru Dan Loeb leads Third Point LLC and recently built up a large stake in Baxter International (NYSE:BAX), which now makes up about 15% of his portfolio. Since that time he has requested and been granted two board seats and helped to install the new CEO. Loeb has not taken the aggressive approach (given the soft tone of his letter to the company) he is known for that usually tends to grab the attention of the financial media. It’s a bit of a stretch to say this one is flying under the radar, but it definitely has not attracted as much attention as his Sotheby’s (BID) or Sony campaigns. Read more...
Vanguard Health Care Fund Buys Biogen and Mylan, Cuts Pfizer Its largest trades include Merck, HCA, Baxter
Edward Owens has worked in investment management for more than 30 years. He has managed the Vanguard Health Care Fund (Trades, Portfolio) since its inception in May 1984. The hedge fund has a portfolio composed of 82 stocks with a total value of $46,362 million and the following are the most weighted trades based on the impact on the portfolio during the third quarter. Read more...
Weekly Three-Year Low Highlights Baxter International, Leucadia National, Colfax, Rent-A-Center tumble
According to GuruFocus list of 3-year lows, Baxter International Inc. (NYSE:BAX), Leucadia National (NYSE:LUK) (Trades, Portfolio), Colfax Corp. (NYSE:CFX) and Rent-A-Center Inc. (NASDAQ:RCII) have all reached their three-year highs. Read more...
Guru Stocks at 52-Week Lows Baxter International, Macy's lead the list
According to GuruFocus list of 52-week lows, these Guru stocks have reached their 52-week lows. Read more...
Activist Hedge Fund Manager Dan Loeb Increases Position in Leading Biotech Company Relative valuation metrics are showing a good entry point in this stock
Daniel Loeb’s Third Point LLC disclosed Wednesday that he increased his stake in Baxter International Inc. (NYSE:BAX), a medical equipment and supplies company, by purchasing an additional 11.97 million shares at an average price of $32.69 per share. Read more...
The Best Companies of the Medical Industry – September 2015 Five companies identified as suitable for defensive and enterprising investors
While ModernGraham supports the bottom-up approach to investing, many investors do utilize the top-down method, whereby an industry is selected before the company itself. With that in mind, here is a look at the best companies of the medical industry, selecting the most promising investment opportunities within that industry and giving a broad look at the industry as a whole. Read more...
Scott Black Sells Stakes in 10 Companies
Scott Black (Trades, Portfolio), Delphi Management’s chairman, president, chief investment officer and chief compliance officer, is a value investor, and he did buy some new stakes and add to existing ones in the second quarter – but he also sold some significant stakes in his portfolio. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 6.24
BAX's P/E(ttm) is ranked higher than
57% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.93 vs. BAX: 6.24 )
Ranked among companies with meaningful P/E(ttm) only.
BAX' s P/E(ttm) Range Over the Past 10 Years
Min: 6.6  Med: 10.28 Max: 25.25
Current: 6.24
6.6
25.25
Forward P/E 26.32
BAX's Forward P/E is ranked lower than
81% of the 37 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.08 vs. BAX: 26.32 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 6.26
BAX's PE(NRI) is ranked higher than
56% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.93 vs. BAX: 6.26 )
Ranked among companies with meaningful PE(NRI) only.
BAX' s PE(NRI) Range Over the Past 10 Years
Min: 6.58  Med: 11.81 Max: 115.67
Current: 6.26
6.58
115.67
Price/Owner Earnings (ttm) 34.55
BAX's Price/Owner Earnings (ttm) is ranked lower than
63% of the 79 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.52 vs. BAX: 34.55 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
BAX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 7.61  Med: 11.81 Max: 34.55
Current: 34.55
7.61
34.55
P/B 2.74
BAX's P/B is ranked higher than
50% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. BAX: 2.74 )
Ranked among companies with meaningful P/B only.
BAX' s P/B Range Over the Past 10 Years
Min: 2.05  Med: 2.63 Max: 3.34
Current: 2.74
2.05
3.34
P/S 1.91
BAX's P/S is ranked higher than
60% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.46 vs. BAX: 1.91 )
Ranked among companies with meaningful P/S only.
BAX' s P/S Range Over the Past 10 Years
Min: 1.06  Med: 1.51 Max: 2.34
Current: 1.91
1.06
2.34
PFCF 33.05
BAX's PFCF is ranked lower than
58% of the 77 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.13 vs. BAX: 33.05 )
Ranked among companies with meaningful PFCF only.
BAX' s PFCF Range Over the Past 10 Years
Min: 6.96  Med: 11.29 Max: 266.13
Current: 33.05
6.96
266.13
POCF 14.75
BAX's POCF is ranked higher than
56% of the 102 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 15.65 vs. BAX: 14.75 )
Ranked among companies with meaningful POCF only.
BAX' s POCF Range Over the Past 10 Years
Min: 4.58  Med: 7.04 Max: 14.75
Current: 14.75
4.58
14.75
EV-to-EBIT 17.13
BAX's EV-to-EBIT is ranked higher than
65% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.92 vs. BAX: 17.13 )
Ranked among companies with meaningful EV-to-EBIT only.
BAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2828.6  Med: 9.20 Max: 61.4
Current: 17.13
-2828.6
61.4
EV-to-EBITDA 10.88
BAX's EV-to-EBITDA is ranked higher than
74% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.78 vs. BAX: 10.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.8  Med: 7.10 Max: 43.9
Current: 10.88
4.8
43.9
Shiller P/E 13.02
BAX's Shiller P/E is ranked higher than
90% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 38.88 vs. BAX: 13.02 )
Ranked among companies with meaningful Shiller P/E only.
BAX' s Shiller P/E Range Over the Past 10 Years
Min: 9.71  Med: 13.02 Max: 21.84
Current: 13.02
9.71
21.84
Current Ratio 2.05
BAX's Current Ratio is ranked lower than
63% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.68 vs. BAX: 2.05 )
Ranked among companies with meaningful Current Ratio only.
BAX' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.60 Max: 2.05
Current: 2.05
1.08
2.05
Quick Ratio 1.77
BAX's Quick Ratio is ranked higher than
53% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.70 vs. BAX: 1.77 )
Ranked among companies with meaningful Quick Ratio only.
BAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.17 Max: 1.77
Current: 1.77
0.74
1.77
Days Inventory 140.11
BAX's Days Inventory is ranked higher than
50% of the 188 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.91 vs. BAX: 140.11 )
Ranked among companies with meaningful Days Inventory only.
BAX' s Days Inventory Range Over the Past 10 Years
Min: 99.71  Med: 138.80 Max: 219.03
Current: 140.11
99.71
219.03
Days Sales Outstanding 69.12
BAX's Days Sales Outstanding is ranked higher than
56% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.39 vs. BAX: 69.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.53  Med: 65.15 Max: 112.88
Current: 69.12
58.53
112.88
Days Payable 41.05
BAX's Days Payable is ranked lower than
70% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 56.99 vs. BAX: 41.05 )
Ranked among companies with meaningful Days Payable only.
BAX' s Days Payable Range Over the Past 10 Years
Min: 39.5  Med: 46.78 Max: 76.67
Current: 41.05
39.5
76.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.96
BAX's Dividend Yield is ranked higher than
82% of the 141 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.34 vs. BAX: 1.96 )
Ranked among companies with meaningful Dividend Yield only.
BAX' s Dividend Yield Range Over the Past 10 Years
Min: 2.09  Med: 3.85 Max: 5.89
Current: 1.96
2.09
5.89
Dividend Payout 1.76
BAX's Dividend Payout is ranked lower than
92% of the 90 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.38 vs. BAX: 1.76 )
Ranked among companies with meaningful Dividend Payout only.
BAX' s Dividend Payout Range Over the Past 10 Years
Min: 0.27  Med: 0.45 Max: 3.37
Current: 1.76
0.27
3.37
Dividend Growth (3y) -6.80
BAX's Dividend Growth (3y) is ranked lower than
81% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.90 vs. BAX: -6.80 )
Ranked among companies with meaningful Dividend Growth (3y) only.
BAX' s Dividend Growth (3y) Range Over the Past 10 Years
Min: -6.8  Med: 1.70 Max: 22.5
Current: -6.8
-6.8
22.5
Forward Dividend Yield 1.04
BAX's Forward Dividend Yield is ranked lower than
62% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. BAX: 1.04 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.61
BAX's Yield on cost (5-Year) is ranked higher than
75% of the 168 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.73 vs. BAX: 2.61 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
BAX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 2.61  Med: 5.13 Max: 7.85
Current: 2.61
2.61
7.85
3-Year Average Share Buyback Ratio 0.40
BAX's 3-Year Average Share Buyback Ratio is ranked higher than
85% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.40 vs. BAX: 0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.6  Med: 0.80 Max: 7.7
Current: 0.4
-10.6
7.7

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 5.04
BAX's Price/Tangible Book is ranked lower than
56% of the 167 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. BAX: 5.04 )
Ranked among companies with meaningful Price/Tangible Book only.
BAX' s Price/Tangible Book Range Over the Past 10 Years
Min: 3.9  Med: 5.33 Max: 10.45
Current: 5.04
3.9
10.45
Price/Projected FCF 0.96
BAX's Price/Projected FCF is ranked higher than
87% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.93 vs. BAX: 0.96 )
Ranked among companies with meaningful Price/Projected FCF only.
BAX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.63  Med: 1.09 Max: 2.35
Current: 0.96
0.63
2.35
Price/Median PS Value 1.26
BAX's Price/Median PS Value is ranked lower than
61% of the 163 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.11 vs. BAX: 1.26 )
Ranked among companies with meaningful Price/Median PS Value only.
BAX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.71  Med: 1.00 Max: 1.57
Current: 1.26
0.71
1.57
Price/Graham Number 3.71
BAX's Price/Graham Number is ranked lower than
72% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.48 vs. BAX: 3.71 )
Ranked among companies with meaningful Price/Graham Number only.
BAX' s Price/Graham Number Range Over the Past 10 Years
Min: 1.16  Med: 1.93 Max: 5.55
Current: 3.71
1.16
5.55
Earnings Yield (Greenblatt) (%) 5.80
BAX's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. BAX: 5.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
BAX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 10.80 Max: 16.9
Current: 5.8
1.6
16.9
Forward Rate of Return (Yacktman) (%) -6.86
BAX's Forward Rate of Return (Yacktman) (%) is ranked lower than
82% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 10.24 vs. BAX: -6.86 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
BAX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -6.9  Med: 14.35 Max: 28
Current: -6.86
-6.9
28

More Statistics

Revenue(Mil) $12747
EPS $ 1.75
Beta0.79
Short Percentage of Float4.07%
52-Week Range $32.18 - 44.78
Shares Outstanding(Mil)547.87

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 9,889 10,167 10,564
EPS($) 1.49 1.68 1.94
EPS without NRI($) 1.49 1.68 1.94

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NYSE:BDX, XPAR:EI, NAS:ILMN, OCSE:COLO B, TSE:4543 » details
Traded in other countries:BTL.Germany, BAX.Mexico, BAX.Switzerland, 0QK8.UK,
Baxter International Inc was incorporated in Delaware in 1931. The Company is a healthcare company. It is engaged in the development, manufacture and sale of products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. The Company applies a combination of medical devices, pharmaceuticals and biotechnology to create products that advance patient care. These products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, clinical and medical research laboratories, and by patients at home under physician supervision. The Company operates in two segments namely BioScience and Medical Products. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as bio surgery products; and vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics, as well as products and services related to pharmacy compounding, drug formulation and packaging technologies. The business manufactures solutions and other products for peritoneal dialysis, a home-based therapy, and also distributes products for hemodialysis, which is generally conducted in a hospital or clinic. The Company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. The Company faces substantial competition in each of its segments from international and domestic healthcare and pharmaceutical companies of all sizes. The BioScience segment faces competitors from pharmaceutical, biotechnology and other companies. The Medical Products segment faces competition from medical device manufacturers and pharmaceutical companies. The Company's operations and many of the products manufactured or sold by the Company are subject to extensive regulation by numerous government agencies, both within and outside the United States.
» More Articles for BAX

Headlines

Articles On GuruFocus.com
Dan Loeb's Third Point Portfolio Highly Concentrated Apr 01 2016 
Daniel Loeb's Third Point Portfolio Highly Concentrated Mar 31 2016 
Jana Partners Trims Qualcomm Holding by 67% Mar 24 2016 
Charles Brandes Ups Several Stakes for Consecutive Quarters Jan 20 2016 
Jana Partners Beefs Up Stake in ConAgra Foods Dec 07 2015 
Why Daniel Loeb is Putting 15% of His Portfolio Into Baxter Nov 15 2015 
Vanguard Raises Stakes in Biogen, Mylan, Merck Nov 15 2015 
Diamond Hill Adds to Stake in Automotive Parts Company Nov 12 2015 
Third Point's Third Quarter Letter Nov 02 2015 
Vanguard Health Care Fund Buys Biogen and Mylan, Cuts Pfizer Nov 02 2015 

More From Other Websites
Baxter Exhibits Strong 1Q16 Performance, Beat Estimates Apr 28 2016
'Mad Money' Lightning Round: Take Chubb Over AIG Apr 28 2016
BAXTER INTERNATIONAL INC Files SEC form 8-K, Temporary Suspension of Trading Under Registrant's... Apr 27 2016
Baxter International, Inc. :BAX-US: Earnings Analysis: Q1, 2016 By the Numbers Apr 27 2016
Baxter Raises Guidance As Hospital Market Rebounds; Stock Hits High Apr 26 2016
Baxter (BAX) Stock Rises on Q1 Earnings Beat, Higher Forecast Apr 26 2016
Edited Transcript of BAX earnings conference call or presentation 26-Apr-16 12:30pm GMT Apr 26 2016
Here's Why You Should Pass on Baxter's Stock Despite Healthy First Quarter Earnings Apr 26 2016
Baxter International (BAX) Q1 Earnings, Sales Beat; View Up Apr 26 2016
The Zacks Analyst Blog Highlights: St. Jude Medical, Stryker, Baxter International, Boston... Apr 26 2016
Baxter International (BAX) Beats Q1 Earnings & Sales Apr 26 2016
Baxter International Inc Earnings Call scheduled for 8:30 am ET today Apr 26 2016
Baxter lifts 2016 adjusted profit forecast after strong quarter Apr 26 2016
Baxter Reports First Quarter 2016 Results and Provides Updated Financial Outlook for Full-Year 2016 Apr 26 2016
Baxter tops Street 1Q forecasts Apr 26 2016
Baxter tops Street 1Q forecasts Apr 26 2016
Baxter's sales dip 1 pct, hurt by strong dollar Apr 26 2016
BAXTER INTERNATIONAL INC Files SEC form 8-K, Results of Operations and Financial Condition,... Apr 26 2016
Q1 2016 Baxter International Inc Earnings Release - Time Not Supplied Apr 26 2016
Baxter Reports First Quarter 2016 Results and Provides Updated Financial Outlook for Full-Year 2016 Apr 26 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK